Fertility warning
This medicine may affect fertility.
Leaflet BENDAMUSTINA ACCORD 25mg / ml concentrate for solution for infusion
- Product code:
- W68870002
- Quantity:
- 5
- Indicated for:
- hematologic malignancies
- Route of administration:
- infusion
- Substance:
- bendamustine (alkylating antineoplastic agent)
- ATC
- L01AA09 — Antineoplastic and immunomodulating agents | Alkylating agents | Nitrogen mustard analogues
Precautions:
Dose adjustment in hepatic impairment
Dose adjustment may be needed in liver disease.
Cytotoxic / special handling
Handle with special care.
Contraception required
Effective contraception is required during treatment.
Contraindicated during breastfeeding
Do not use this medicine while breastfeeding.
Contraindicated during pregnancy
Do not use this medicine during pregnancy.
Hepatotoxicity
This medicine may affect the liver.
Major drug interactions
This medicine may have important interactions with other medicines.
Myelosuppression / agranulocytosis
This medicine may lower blood cell counts.
Additional monitoring
This medicine is subject to additional monitoring.
Requires periodic laboratory tests
Periodic laboratory tests may be required during treatment.
Severe skin reactions
Stop taking the medicine and seek urgent medical help if a severe rash occurs.
Bendamustine is a medication used for the treatment of certain types of cancer, including non-Hodgkin's lymphoma, chronic lymphocytic leukemia, and multiple myeloma. It is an alkylating chemotherapeutic agent that interferes with the DNA of cancer cells, inhibiting cell division and causing cell death.
The medication is administered via intravenous infusion, usually in treatment cycles, as directed by a doctor. The dosage and duration of treatment are adjusted based on the type of cancer and the patient's response.
Common side effects include nausea, vomiting, fatigue, decreased blood cell counts, and infections. In rare cases, more severe adverse effects such as liver failure or severe allergic reactions may occur.
Bendamustine is not recommended for pregnant or breastfeeding women, as it may affect fetal development. Patients should inform their doctor about all medications they are taking to avoid drug interactions.
The medication is administered via intravenous infusion, usually in treatment cycles, as directed by a doctor. The dosage and duration of treatment are adjusted based on the type of cancer and the patient's response.
Common side effects include nausea, vomiting, fatigue, decreased blood cell counts, and infections. In rare cases, more severe adverse effects such as liver failure or severe allergic reactions may occur.
Bendamustine is not recommended for pregnant or breastfeeding women, as it may affect fetal development. Patients should inform their doctor about all medications they are taking to avoid drug interactions.
General data about BENDAMUSTINA ACCORD 25mg / ml
- Substance:
- bendamustine
- Date of latest medicines list:
- 01-06-2026
- Product code:
- W68870002
- Concentration:
- 25mg / ml
- Pharmaceutical form:
- concentrate for solution for infusion
- Quantity:
- 5
- Product type:
- Generic medicine
- Price:
- 1044.63 RON
- Prescription status:
- P-RF — Medicines dispensed with a medical prescription that is retained by the pharmacy and cannot be renewed.
Pharmaceutical forms available for bendamustine
Concentrations available for bendamustine
- 2.5mg/ml
- 25mg/ml